A phase II clinical trial of anti-Tac(Fv)-PE38 (LMB-2) immunotoxin for treatment of CD25 positive chronic lymphocytic leukemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-Tac Fv PE38 conjugate (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 23 Jan 2018 Biomarkers information updated
- 14 Dec 2011 Actual patient number is 15 according to ClinicalTrials.gov.
- 14 Dec 2011 Actual patient number is 15 according to ClinicalTrials.gov.